Testosterone
Anabolic-Androgenic Steroid | Primary Male Sex Hormone
Community Research
Join others researching Testosterone — share findings, ask questions, and learn from real experiences
Testosterone is the primary endogenous androgenic-anabolic steroid hormone produced mainly by the Leydig cells of the testes in males and in smaller quantities by the ovaries and adrenal glands in females. It is essential for the development and maintenance of male reproductive tissues, secondary sexual characteristics, muscle mass, bone density, red blood cell production, and overall well-being. Exogenous testosterone has been FDA-approved for the treatment of male hypogonadism since the 1950s and remains the gold standard for testosterone replacement therapy (TRT). It is available in multiple pharmaceutical formulations including intramuscular injectables, transdermal gels, transdermal patches, subcutaneous pellets, and oral capsules. In supraphysiological doses, testosterone is also widely used for performance enhancement, though such use falls outside approved medical indications.
Testosterone exerts its effects primarily through binding to the intracellular androgen receptor (AR), forming a hormone-receptor complex that translocates to the nucleus and modulates gene transcription. This drives protein synthesis in skeletal muscle (anabolic effect), stimulates erythropoietin production in the kidneys to increase red blood cell mass, promotes osteoblast activity and bone mineral density, and regulates libido and cognitive function. Testosterone is also converted to dihydrotestosterone (DHT) by the enzyme 5-alpha reductase in peripheral tissues (skin, prostate, hair follicles), where DHT mediates androgenic effects with greater potency. Additionally, testosterone is aromatized to estradiol by the enzyme aromatase in adipose tissue, which is important for bone health, lipid metabolism, and cardiovascular function but can cause estrogenic side effects at supraphysiological doses.
Molecular Data
Research Indications
Testicular failure resulting in low testosterone production. Caused by Klinefelter syndrome, undescended testes, testicular injury, or orchitis. Testosterone replacement restores normal androgen levels.
Hypothalamic or pituitary dysfunction leading to insufficient LH/FSH signaling. Caused by pituitary tumors, head trauma, obesity, or idiopathic HPA axis dysfunction. Often combined with HCG if fertility preservation is desired.
Gradual decline in testosterone production beginning around age 30, accelerating after 50. Symptoms include fatigue, reduced libido, loss of muscle mass, and increased body fat. TRT can reverse symptomatic decline when levels fall below reference ranges.
Short-term testosterone therapy to initiate puberty in adolescent males with constitutional delay, promoting secondary sexual characteristics and growth.
Prevention and reversal of sarcopenia and muscle wasting in hypogonadal men. Physiological replacement doses increase lean body mass by 3-5 kg over 6-12 months.
TRT reduces total body fat and visceral adiposity in hypogonadal men, with the greatest reductions seen in those with metabolic syndrome or obesity.
Dose-dependent increases in muscle strength, particularly in the upper body. Effects are more pronounced at supraphysiological doses but clinically meaningful at replacement levels.
Improvement in erectile function in men with documented low testosterone. Most effective when combined with PDE5 inhibitors in men who do not fully respond to TRT alone.
Consistent and reliable improvement in sexual desire, arousal, and frequency of sexual activity. Often the earliest symptomatic improvement noticed on TRT.
Improved orgasmic function, intercourse satisfaction, and overall sexual well-being in hypogonadal men.
TRT improves insulin sensitivity, fasting glucose, and HbA1c in hypogonadal men with or at risk for type 2 diabetes.
Reduction in waist circumference, triglycerides, and inflammatory markers with long-term TRT in men with metabolic syndrome.
Increases in lumbar spine and femoral neck bone mineral density over 12-36 months of therapy, reducing fracture risk in severely hypogonadal men.
Improvement in depressive symptoms, particularly in men with documented low testosterone. Not a substitute for standard antidepressant therapy in eugonadal men.
Some evidence for improved spatial memory and verbal fluency with testosterone normalization, though results in clinical trials have been mixed.
Reduced fatigue and improved overall sense of vitality and well-being, commonly reported within the first 3-6 weeks of therapy.
Dosing Protocols
Intramuscular or subcutaneous injection of esterified testosterone is the most common and cost-effective route of administration. Testosterone cypionate and enanthate are the most widely prescribed esters, offering steady serum levels with weekly or biweekly dosing. Subcutaneous injection has become increasingly popular due to comparable pharmacokinetics, more stable levels, and reduced injection discomfort.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| TRT - Standard Replacement | 100-200 mg/week | 1-2x per week | IM or SubQ (cypionate or enanthate) |
| TRT - Conservative Start | 80-100 mg/week | 2x per week (40-50 mg per injection) | SubQ or shallow IM |
| TRT - Propionate Protocol | 25-50 mg every other day | Every other day or 3x per week | SubQ or shallow IM |
| Performance Enhancement - Moderate | 300-500 mg/week | 2x per week | IM (cypionate or enanthate) |
| Performance Enhancement - Advanced | 500-750 mg/week | 2-3x per week | IM (cypionate or enanthate) |
Reconstitution Instructions
- Pre-filled testosterone vial (typically 200 mg/mL in 1 mL or 10 mL vials)
- Syringes (1 mL or 3 mL)
- Drawing needle (18-21 gauge)
- Injection needle (25-30 gauge for SubQ, 22-25 gauge for IM)
- Alcohol swabs
- Sharps container
- 1 Wash hands thoroughly and prepare a clean work surface
- 2 Wipe vial stopper with alcohol swab and allow to dry
- 3 Draw air into syringe equal to the volume of testosterone to be withdrawn
- 4 Insert drawing needle through vial stopper and inject air to equalize pressure
- 5 Invert vial and withdraw the prescribed dose, tapping to remove air bubbles
- 6 Switch to injection needle (do not inject with drawing needle)
- 7 Clean injection site with alcohol swab in circular motion outward
- 8 For SubQ: pinch skin at 45-degree angle in abdomen, upper thigh, or love handles
- 9 For IM: insert at 90-degree angle into ventrogluteal, vastus lateralis, or deltoid
- 10 Aspirate briefly (optional per current guidelines), then inject slowly over 10-20 seconds
- 11 Withdraw needle, apply gentle pressure with gauze, dispose of needle in sharps container
Protocol Variations
Multiple approaches exist - compare before choosing
Different sources recommend different protocols for this peptide. Review each approach and consider your goals, tolerance, and experience level before choosing.
Testosterone Cypionate
TraditionalSource: Standard TRT Protocol
"Most commonly prescribed ester in the US. Long half-life allows weekly or biweekly injections with stable blood levels."
Cypionate is the most widely prescribed testosterone ester in the United States. Its 8-day half-life provides relatively stable serum levels with once or twice weekly injections. Available as Depo-Testosterone (brand) and generic formulations in cottonseed or sesame oil carriers.
Key Points
- Half-life: ~8 days — supports weekly or biweekly injection schedules
- Carrier oil: typically cottonseed oil (Depo-Testosterone) or sesame oil
- Most commonly available ester at US pharmacies and clinics
- Slightly longer half-life than enanthate, though clinically interchangeable
- Available in 100mg/mL and 200mg/mL concentrations
Dosing Schedule
Testosterone Enanthate
AlternativeSource: International Standard
"The global standard for injectable testosterone. Virtually interchangeable with cypionate but more widely available internationally."
Enanthate is the most widely used testosterone ester worldwide and the standard in most countries outside the US. Its pharmacokinetic profile is nearly identical to cypionate with a 7-8 day half-life. Available as Delatestryl (brand) and numerous international generics.
Key Points
- Half-life: ~7-8 days — virtually identical to cypionate in practice
- Carrier oil: typically sesame oil
- Global standard — more widely available internationally than cypionate
- Slightly lower molecular weight means marginally more testosterone per mg
- Can be used interchangeably with cypionate at the same dose
Dosing Schedule
Testosterone Propionate
AlternativeSource: Short Ester Protocol
"Faster-acting ester that clears quickly. Useful for dialing in dose response, managing side effects, and at the end of cycles before PCT."
Propionate is the shortest commonly used testosterone ester with a 2-3 day half-life. It requires more frequent injections (every other day or every day) but allows for faster dose adjustments and clears the system quickly. Often preferred at the end of a cycle before PCT, or by those who want rapid dose titration.
Key Points
- Half-life: ~2-3 days — requires every-other-day or daily injection
- Fastest onset of all common esters — peak levels within 24-48 hours
- Clears the system in ~10 days — allows faster transition to PCT
- Higher mg-for-mg testosterone content due to lighter ester weight
- Known for more injection site pain (PIP) due to shorter ester chain
- Useful for initial TRT dose-finding before switching to longer esters
Dosing Schedule
Testosterone Undecanoate
AlternativeSource: Long-Acting / Oral Protocol
"Ultra-long-acting injectable or oral formulation for maximum convenience. Fewer injections per year but less flexibility for dose adjustments."
Undecanoate is available in two formulations: an ultra-long-acting injectable (Nebido/Aveed) with a half-life of ~21 days given every 10-14 weeks, and an oral capsule (Jatenzo) taken twice daily with food. The injectable version offers maximum convenience with only 4-6 injections per year but requires clinic administration and offers limited dose flexibility.
Key Points
- Injectable half-life: ~21 days — injection every 10-14 weeks (Nebido/Aveed)
- Oral half-life: ~6 hours — requires twice daily dosing with fatty meal (Jatenzo)
- Injectable must be administered in a clinical setting (REMS program for Aveed in US)
- Oral form avoids first-pass liver toxicity via lymphatic absorption
- Least flexibility for dose adjustment due to depot effect
- Highest convenience for patients who dislike frequent injections
Dosing Schedule
Interactions
What to Expect
Side Effects & Safety
Common Side Effects
- Acne and oily skin (increased sebum production via DHT)
- Water retention and bloating (estrogen-mediated)
- Mild mood changes (irritability, increased assertiveness)
- Increased hematocrit and hemoglobin (erythrocytosis)
- Testicular atrophy (suppression of LH/FSH from exogenous testosterone)
- Injection site pain, redness, or irritation
- Increased body hair growth
- Mild elevation in blood pressure
Stop Signs - Discontinue if:
- Severe chest pain, tightness, or pressure
- Sudden difficulty breathing or shortness of breath at rest
- Swelling, warmth, or pain in one leg (potential deep vein thrombosis)
- Severe persistent headaches or visual disturbances
- Yellowing of skin or eyes (jaundice)
- Blood in urine or significant urinary obstruction
- Signs of stroke: sudden numbness, confusion, trouble speaking, loss of coordination
Contraindications
- Prostate cancer (active or history of hormone-sensitive prostate cancer)
- Breast cancer in males
- Polycythemia (hematocrit above 54% at baseline)
- Uncontrolled severe heart failure
- Untreated severe obstructive sleep apnea
- Desire for near-term fertility (without concurrent HCG/FSH)
- Pregnancy or potential exposure to pregnant women (Category X)
- Hypersensitivity to testosterone or any formulation components
Quality Checklist
Good Signs
- Clear, pale yellow to yellow oil with no visible particles or cloudiness
- Pharmaceutical-grade product with valid NDC number and manufacturer lot
- Proper labeling with concentration (typically 200 mg/mL), ester type, and expiration date
- Intact rubber stopper with no signs of puncture prior to first use
- Oil draws smoothly with appropriate viscosity (carrier oils: cottonseed, grapeseed, or sesame)
- Prescribed by licensed physician with documented lab work indicating need
Warning Signs
- Underground lab (UGL) product without pharmaceutical-grade verification
- Concentration claims above 300 mg/mL (higher concentrations often cause severe PIP)
- Vial label with spelling errors, misaligned printing, or unprofessional appearance
- Oil appears slightly darker than expected but is otherwise clear
Bad Signs
- Cloudy, discolored, or particulate-containing solution (contamination risk)
- Crashed gear (crystallized testosterone visible in vial) without proper reheating
- Broken or missing tamper-evident seal on vial
- No labeling, incorrect labeling, or missing expiration date
- Pain, redness, or swelling at injection site lasting more than 48-72 hours (potential infection or abscess)
- Product sourced without any testing or third-party verification
References
- Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice GuidelineBhasin, S., Brito, J.P., Cunningham, G.R., et al.The Journal of Clinical Endocrinology & Metabolism (2018)
Comprehensive clinical practice guideline recommending testosterone therapy for men with symptomatic testosterone deficiency confirmed by consistently low morning serum testosterone levels. Provides evidence-based protocols for diagnosis, treatment, and monitoring.
- Effects of Testosterone Treatment in Older MenSnyder, P.J., Bhasin, S., Cunningham, G.R., et al.The New England Journal of Medicine (2016)
The Testosterone Trials (TTrials) in 790 men aged 65+ with low testosterone showed that 1 year of testosterone gel treatment improved sexual function, physical activity, vitality, and mood compared to placebo. The largest coordinated set of testosterone trials in older men to date.
- Testosterone Treatment and Cardiovascular Events in Men with Low Testosterone: The TRAVERSE Randomized Clinical TrialLincoff, A.M., Bhasin, S., Flevaris, P., et al.The New England Journal of Medicine (2023)
Landmark cardiovascular safety trial (TRAVERSE) in 5,246 men aged 45-80 with hypogonadism and elevated cardiovascular risk. Testosterone replacement was noninferior to placebo for major adverse cardiovascular events (MACE), resolving longstanding safety concerns about testosterone and cardiovascular risk.
- Testosterone dose-response relationships in healthy young menBhasin, S., Woodhouse, L., Casaburi, R., et al.American Journal of Physiology - Endocrinology and Metabolism (2001)
Demonstrated dose-dependent increases in lean body mass, muscle strength, and fat-free mass in healthy young men receiving graded doses of testosterone enanthate (25 to 600 mg/week) over 20 weeks, establishing the dose-response relationship for testosterone's anabolic effects.
- Testosterone Replacement Therapy and Cardiovascular Risk: A ReviewCorona, G., Torres, L.O., Maggi, M.The World Journal of Men's Health (2020)
Systematic review of cardiovascular risk associated with TRT, concluding that normalization of testosterone levels is not associated with increased cardiovascular risk and may provide cardiovascular benefits in hypogonadal men, particularly regarding metabolic syndrome, insulin resistance, and body composition.
Related Peptides
Disclaimer
This information is for educational and research purposes only. Consult a healthcare professional before use.